TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02772211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained.~After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained.~After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Following completion of Ketamine infusions. patients in the experimental group will start receiving D-cycloserine pills titrated slowly up to 1000mg/d over the next 8 weeks \[2\] in the following manner:~1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~3. Week 7: Day 43-49 - 750mg/d, three pills per day~4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks \[2\] in the following manner:~1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~3. Week 7: Day 43-49 - 750mg/d, three pills per day~4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day
Study: NCT04173156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labrida Bioclean
Description: The brush bristles of the test device (Labrida BioClean®, LABRIDA, Oslo, Norway) are made of the biopolymer chitosan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gracey Periodontal curettes
Description: Regular commercially available area specific and medical grade steel Gracey periodontal curettes
Study: NCT03185195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125 Oral Tablet
Description: Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-AQX-1125 IV
Description: Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-AQX-1125 Oral Solution
Description: Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
Study: NCT00813254

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
Study: NCT00077298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03408301

Intervention type: PROCEDURE
Intervention: Tourniquet deflation
Description: Tourniquet deflation
Study: NCT02812069

Intervention type: DEVICE
Group type: OTHER
Intervention: ThermaZone® Device
Description: The device will be used to intraoperatively warm patients having minor-to moderate surgical procedures
Study: NCT03019133

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sound reduction
Description: Subjects will wear noise reduction headphones between the hours of 8:00 pm and 8:00 am.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sound masking
Description: Subjects will wear wear headphones playing relaxing music between the hours of 8:00 pm and 8:00 am.
Study: NCT02284061

Intervention type: OTHER
Group type: OTHER
Intervention: physical activities adapted to children

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activities adapted to children
Study: NCT01386385

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-conformal RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT00103246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silicon phthalocyanine 4
Description: Participants receive topical silicon phthalocyanine 4 (Pc 4). One hour later, participants undergo photodynamic therapy. Treatment repeats weekly for up to 3 weeks (up to 3 total treatments for the same lesion OR up to 3 lesions treated if multiple lesions are present).Cohorts of 3 participants receive escalating doses of Pc 4 and visible light until the maximum tolerated dose (MTD) is determined.
Study: NCT02527798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Cohort 1
Description: furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Cohort 2
Description: furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Cohort 3
Description: furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar water will be administered in a equivalent volume as drug intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar water will be administered in a equivalent volume as drug intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar water will be administered in a equivalent volume as drug intervention.
Study: NCT04704375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio Electro-Magnetic Regulation (BEMER) Therapy
Description: BEMER is a therapeutic modality that deploys a biorhythmically defined stimulus through Pulsed Electromagnetic Field (PEMF). This stimulus has a targeted effect on the microvasculature, and the primary effect is an improvement in tissue microcirculation. The positive effects of vasomotion on the microcirculation has been shown to result in significant increases in arteriovenous oxygen difference, number of open capillaries, arteriolar and venular flow volume, and flow rate of red blood cells in the microvasculature. Therefore, BEMER can potentially be used in the treatment of LBP by improving microcirculation in muscular tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio Electro-Magnetic Regulation (BEMER) Therapy
Description: BEMER is a therapeutic modality that deploys a biorhythmically defined stimulus through Pulsed Electromagnetic Field (PEMF). This stimulus has a targeted effect on the microvasculature, and the primary effect is an improvement in tissue microcirculation. The positive effects of vasomotion on the microcirculation has been shown to result in significant increases in arteriovenous oxygen difference, number of open capillaries, arteriolar and venular flow volume, and flow rate of red blood cells in the microvasculature. Therefore, BEMER can potentially be used in the treatment of LBP by improving microcirculation in muscular tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OMT (osteopathic manipulative treatment)
Description: i. OMT Myofascial release (MFR), soft tissue (ST) release, muscle energy (ME), counterstrain (CS), and balanced ligamentous tension (BLT) technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OMT (osteopathic manipulative treatment)
Description: i. OMT Myofascial release (MFR), soft tissue (ST) release, muscle energy (ME), counterstrain (CS), and balanced ligamentous tension (BLT) technique.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Light touch
Description: Treaters will place their hands lightly on the subject's lumbar paraspinal muscles in the supine and prone positions in the same area as where one would place your hands for lumbar MFR technique for the same amount of time as it would take to perform MFR in this area (approximately 5 minutes). However, no lifting or action will be done. In addition, the subject will lie down on the BEMER mat (as they would do during a BEMER session), but the device will not be activated.
Study: NCT00605436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restorative yoga therapy
Description: 3-hour workshop at study initiation. Then twice-weekly group yoga classes for 5 weeks, then once-weekly group yoga classes for 5 weeks. Home yoga practice for 90 minutes/week throughout the 10 week trial.
Study: NCT01368705

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard protein delivery
Description: Protein delivery of 1.5 g/kg/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 1 (2.2g/kg/day)
Description: protein delivery of 2.2g/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 2 (3.0 g/kg/day)
Description: protein delivery of 3.0 g/kg/day
Study: NCT01348620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)
Description: Single port laparoscopic cholecystectomy. SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson \& Johnson Medical Spa)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four port laparoscopic cholecystectomy surgery
Description: Four port laparoscopic cholecystectomy surgery
Study: NCT00074282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentostatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Study: NCT00975117

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo tablet (Orally administered) twice a day, for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spermotrend
Description: One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
Study: NCT00639717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplant
Description: reduced intensity, matched unrelated donor stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus (standard GVHD prophylaxis)
Description: Tacrolimus(or cyclosporine when necessary)~Tacrolimus will begin on day -3, IV or oral.~Target trough level for tacrolimus is 8-12 ng/ml.~In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate (standard GVHD prophylaxis)
Description: Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxsalen
Description: Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly.~On day +70 post transplant ECP frequency will be given every other week.~On day +100 post transplant ECP will be given monthly until day +180 and stopped.
Study: NCT01756092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Graft
Description: Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
Study: NCT01759589

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: 1 mg/kg propofol IV (over 15 sec) during anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil and propofol
Description: 1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered
Study: NCT05450848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataXRT
Description: StrataXRT is a flexible wound dressing for the prevention and treatment of radiation dermatitis. It is in the form of a gel which, when applied, creates a protective film that maintains skin integrity. The product is used to relieve low grade inflammatory radiation changes such as dry, itching, flaking, peeling and irritated skin. For more severe inflammatory changes with open wound components, StrataXRT reduces pain, redness and heat and helps soothe the exposed skin areas. StrataXRT can be applied where skin integrity has been compromised and may also be used in conjunction with other adjunctive treatments to improve overall results. StrataXRT contains Polydimethylsiloxanes, Siloxanes and Alkylmethyl Silicones and is transparent and odourless. It does not contain alcohols, parabens or fragrances. StrataXRT can be used with or without a secondary protective dressing. It is suitable for children and people with sensitive skin.
Study: NCT03061136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Study: NCT05450848

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sorbolene
Description: Aqueous cream (moisturizer) that soothes itchiness and dryness of the skin, and aids skin hydration. It is non-greasy, fragrance free, colour free, GMO free, paraben free and pH balanced.
Study: NCT02891187

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone follow-up
Description: Patients will be called for postoperative care at 1-2 weeks, 6 weeks, and 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Clinic Visits
Description: Patients will return to the clinic at 1-2 weeks, 6 weeks, and 3 months
Study: NCT04250649

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous tissue disinfection
Description: Skin and subcutaneous incision (up to the muscular fascia) with superficial blade scalpel, disinfection of the subcutaneous tissue with 3cc of Betadine solution, placement of the retractors, dissection and development of the delto-pectoral interval with deep blade scalpel.~When the joint is opened, bacteriological smears are taken from 5 sites in the two groups. 1) exposed subcutaneous tissue, 2) surgeon's gloves (distal end of fingers), 3) superficial blade, 4) deep blade, 5) retractors.~The rest of the shoulder surgery procedure does not differ from what is commonly performed.~The samples are sent to bacteriology for bacterial culture. Anaerobic research is done specifically for P. acnes. The results are considered negative after 10 days.
Study: NCT03194893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
Study: NCT05225493

Intervention type: BEHAVIORAL
Intervention: Peer to peer feedback
Description: HIV experts contact non-HIV specialised treating physicians on individual patient care to recommend HIV testing

Intervention type: BEHAVIORAL
Intervention: Peer to peer feedback
Description: HIV experts contact non-HIV specialised treating physicians on individual patient care to recommend HIV testing

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV rapid test
Description: Free HIV rapid tests are provided to non-HIV specialised treating physicians to use in individual patient care in patients at risk of HIV
Study: NCT03061136

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03839251

Intervention type: DRUG
Group type: OTHER
Intervention: abilify maintena
Description: aripiprazole 400mg or 300mg, IM, Once a month
Study: NCT04443023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chosen TAVI valve
Description: chosen TAVI valve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chosen TAVI valve
Description: chosen TAVI valve
Study: NCT02947126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: Inhaled 7% Hypertonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: Inhaled 7% Hypertonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic Saline
Description: Inhaled 0.9% Isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic Saline
Description: Inhaled 0.9% Isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic Saline
Description: Inhaled 0.9% Isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic Saline
Description: Inhaled 0.9% Isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-DTPA
Description: Inhaled Indium 111 DTPA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-DTPA
Description: Inhaled Indium 111 DTPA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-DTPA
Description: Inhaled Indium 111 DTPA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-DTPA
Description: Inhaled Indium 111 DTPA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Sulfur Colloid
Description: Inhaled Technetium99m sulfur colloid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Sulfur Colloid
Description: Inhaled Technetium99m sulfur colloid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Sulfur Colloid
Description: Inhaled Technetium99m sulfur colloid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Sulfur Colloid
Description: Inhaled Technetium99m sulfur colloid
Study: NCT02789280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activities.
Description: Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait list
Description: will receive the behavioral activation condition after one week of completing baseline assessment.
Study: NCT03100617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial caregiver intervention
Description: Modified version of the REACH-VA intervention for family caregivers of persons with dementia. The intervention has several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
Study: NCT03624101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trikafta
Description: CFTR modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: symdeko/Trikafta
Description: CFTR modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor/Trikafta
Description: CFTR modulator
Study: NCT01024569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Recovery Action Planning (WRAP)
Description: WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks.